
The maker of inhaled insulin Afrezza is betting that relaunching their product and making it a success depends less on diabetics being afraid of needles and more on its clinical advantages over existing insulin.
The maker of inhaled insulin Afrezza is betting that relaunching their product and making it a success depends less on diabetics being afraid of needles and more on its clinical advantages over existing insulin.